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Abstract 
Background: Extracellular peroxiredoxin 1 (Prdx1) has been implicated to play a pivotal role in regulating inflamma‑
tion; however, its function in tissue hypoxia‑induced inflammation, such as severe cardiogenic shock patients, has not 
yet been defined. Thus, the objective of this study was to test the hypothesis that Prdx1 possesses prognostic value 
and instigates systemic inflammatory response syndrome in cardiogenic shock patients undergoing extracorporeal 
membrane oxygenation (ECMO) support.
Methods: We documented the early time course evolution of circulatory Prdx1, hypoxic marker carbonic anhydrase 
IX, inflammatory cytokines including IL‑6, IL‑8, IL‑10, MCP‑1, TNF‑α, IL‑1β, and danger signaling receptors (TLR4 and 
CD14) in a cohort of cardiogenic shock patients within 1 day after ECMO support. In vitro investigations employing 
cultured murine macrophage cell lines and human monocytes were applied to clarify the relationship between Prdx1 
and inflammatory response.
Results: Prdx1 not only peaked earlier than all the other cytokines we studied during the initial course, but also pre‑
dicted a worse outcome in patients who had higher initial Prdx1 plasma levels. The Prdx1 levels in patients positively 
correlated with hypoxic markers carbonic anhydrase IX and lactate, and inflammatory cytokines. In vitro study dem‑
onstrated that hypoxia/reoxygenation induced Prdx1 release from human monocytes and enhanced the responsive‑
ness of the monocytes in Prdx1‑induced cytokine secretions. Furthermore, functional inhibition by Prdx1 antibody 
implicated a crucial role of Prdx1 in hypoxia/reoxygenation‑induced IL‑6 secretion.
Conclusions: Prdx1 release during the early phase of ECMO support in cardiogenic shock patients is associated with 
the development of systemic inflammatory response syndrome and poor clinical outcomes. Thus, circulating Prdx1 
provides not only prognostic information but may be a promising target against ischemia/reperfusion injury.
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Background
Extracorporeal membrane oxygenation (ECMO) is an 
option for patients with refractory cardiogenic shock 
who would otherwise face fatal outcome. Although the 
use of ECMO is trending high worldwide, the associated 
mortality rate remains grave [1, 2]. Therefore, under-
standing the underlying mechanisms which contribute 
to poor clinical outcomes is a pivotal issue to improve 
patient selection as well as further refine this therapeutic 
intervention.
Cardiogenic shock, irrespective of the etiology, is a state 
of systemic hypoperfusion and global tissue ischemia 
[3]. Although ECMO restores oxygenated blood to the 
ischemic tissue, reperfusion paradoxically worsens the 
damages caused by ischemia alone in certain viable cells. 
This ischemia/reperfusion (I/R) injury can be imputed 
to a burst of oxidative stress and development of a sys-
temic inflammatory response syndrome (SIRS), which 
is associated with multisystem organ failure (MOF) and 
considerable mortality [4]. Activation of innate immu-
nity is intimately involved in the deleterious SIRS fol-
lowing I/R [5–8]. Toll like receptor 4 (TLR4), together 
with its co-receptor CD14, plays a central role in innate 
immune response after engagement with lipopolysaccha-
ride (LPS) during sepsis by triggering a signaling cascade 
for inflammation. In addition to LPS, several endogenous 
danger-associated molecular patterns (DAMPs), includ-
ing the newly identified peroxiredoxin-1 (Prdx1), can also 
interact with CD14/TLR4 and elicit severe sepsis-like 
response [9–12].
Prdx1 is a member of the ubiquitous peroxiredoxin 
family proteins which possess antioxidant and chap-
erone activity [13]. In a rat hepatic ischemic model, 
Prdx1 expression and oxidation increase rapidly in liver 
cytosolic extract. Accordingly, a defensive role against 
oxidative stress in cells is suggested based on its peroxi-
dase activity for scavenging endogenous reactive oxy-
gen species (ROS) [14]. By contrast, extracellular release 
of Prdx1 could induce secretion of pro-inflammatory 
cytokines in rats with brain and lung injuries, hence it 
was considered a DAMP molecule [15, 16]. Recent stud-
ies have demonstrated that oxidation is a prerequisite 
for Prdx1 to be secreted by human embryonic kidney 
cells and monocytic cells in response to various stimuli 
[17]. Furthermore, proteomic analysis demonstrates 
that isolated mouse hearts release significant amount of 
Prdx1 into coronary effluent when exposed to I/R [18]. 
Thus, we hypothesized that Prdx1 arises in circulation of 
cardiogenic shock patients who are subjected to whole 
body I/R following ECMO intervention and instigates the 
systemic inflammation. In this study, we investigated the 
early kinetic changes of plasma Prdx1 and inflammatory 
cytokine levels in a cohort of cardiogenic shock patients 
undergoing ECMO. Indeed, there is a close link between 
Prdx1 and inflammatory cytokines which correlated to 
poor clinical outcomes. This result demonstrates that 
Prdx1 serves as an early biomarker for the cardiogenic 
shock patients who receive ECMO support.
Methods
Study population and outcome definition
Adult patients who were admitted to National Taiwan 
University Hospital, a university affiliated tertiary care 
center, for cardiogenic shock or cardiac arrest requir-
ing ECMO support were prospectively enrolled from 
January 2010 to June 2013. ECMO was indicated for 
circulatory collapse or needing more than 40 inotropic 
equivalents (=  dopamine  +  dobutamine  +  epineph-
rine × 100 + norepinephrine × 100, µg/kg/min) support 
[19]. The ECMO system (Medtronic Inc, Minneapolis, 
MN) was set up through femoral veno-arterial route. 
Exclusion criteria included pre-existing MOF and severe 
brain insult before ECMO. All-cause mortality within 
7  days after ECMO initiation was defined as the pri-
mary end point. The survival time of more than 7  days 
was selected to focus on the rescue effect of cardiogenic 
shock by ECMO, and avoid the complications after the 
rescue. Development of MOF is often regarded as irre-
versible damages of cardiogenic shock [20]; therefore, 
all-cause mortality or MOF incompatible with life within 
7 days after ECMO installation was selected as secondary 
end point, and the survival time for those who developed 
MOF within 7  days after ECMO support was defined 
as day 7 for survival analysis although they survived 
more than 7  days. The local research ethics commit-
tee approved this study protocol (Internal Review Board 
number 200911043R), and written informed consents 
were obtained from the closest relatives of the recruited 
patients.
Blood sampling
Peripheral blood samples were withdrawn from patients 
upon ECMO installation before resuscitation (0  h) and 
2, 6, 12, 24 h after oxygenation. Blood samples were col-
lected into ethylenediamine tetraacetic acid (EDTA) con-
taining tubes (Vacutainer, Becton–Dickinson, San Jose, 
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CA), used immediately for flow cytometry analysis, or 
centrifuged at 2000g for 20 min at 4 °C to collect plasma, 
which were aliquoted and stored at −80 °C until analysis.
ROS determination
The blood collected in a sodium heparin containing tube 
(Becton–Dickinson) was kept on ice and analyzed within 
1 h. Total ROS content was measured by reacting 0.2 mL 
of blood with 1 mL of 0.3 mM luminol (Sigma-Aldrich, 
St. Louis, MO) for 4 min at 37 °C in a chemiluminescence 
analyzer (Tohoku Electronic Industrial Co. Ltd., Miyagi, 
Japan). Two measurements with their value difference 
less than 30  % were taken to calculate the average for 
the ROS production. ROS level was expressed as photon 
counts per minute (cpm).
Flow cytometry
One hundred microliters of EDTA anticoagulated whole 
blood was mixed with the following mouse-anti human 
antibodies (BD Biosciences, San Jose, CA): 10 μL of phy-
coerythrin (PE) conjugated anti-CD14, 10  μL of fluo-
rescein isothiocyanate (FITC) conjugated anti-CD16, 
and 12  μL of biotinylated anti-TLR4 antibodies. After 
incubation for 20 min at room temperature in the dark, 
red blood cells were lysed by 1.5 mL of BD lysing buffer, 
and white blood cells were washed twice with 1.5 mL of 
PBS containing 1 % fetal bovine serum and 0.1 % sodium 
azide. After centrifugation, 5  μL of allophycocyanin 
(APC) conjugated streptavidin (BD Biosciences, San Jose, 
CA) was added into the tube containing biotinylated 
anti-TLR4 antibody and incubated for another 20  min. 
The cells were washed and fixed in 0.5  mL of PBS with 
0.25 % paraformaldehyde and kept on 4 °C until analysis. 
Cells were also labelled with negative isotype control for 
PE-mouse IgG1. Flow cytometry data were acquired on 
BD Calibur flow cytometer, and analysis was performed 
using CellQuest software version 3.2. Neutrophils, lym-
phocytes and monocytes were identified based on their 
forward scatter/side scatter (FSC/SSC) dot plot pro-
filing (Additional file  1: Figure S1A). Monocytes were 
further gated in an SSC/CD14+ dot plot while CD14 
positive cells were identified as their CD14 expression 
levels were higher than the isotype-defined fluorescent 
background and cells with granulocytes scattering prop-
erties were excluded (Additional file  1: Figure S1B, C). 
CD14-PE (Additional file 1: Figure S1D) and TLR4-APC 
(Additional file 1: Figure S1E) were measured on CD14+ 
monocytes and expressed as geometric mean fluores-
cence intensity (MFI).
Plasma analysis
Plasma Prdx1 levels were measured by a commercial 
enzyme-linked immunoadsorbent assay (ELISA) kits 
(Northwest Life Science Specialties, Vancouver, WA). 
Carbonic anhydrase IX (CA IX) ELISA kit was from R&D 
Systems (Minneapolis, MN). Plasma cytokine levels were 
determined separately using ELISA kits for tumor necro-
sis factor-α (TNF-α), interleukin (IL)-6, IL-8, IL-10 (BD 
Biosciences), IL-1β and monocyte chemotactic protein 
(MCP)-1 (eBioscience, San Diego, CA).
Cell culture treatment
Human peripheral blood mononuclear cells (PBMCs) 
were isolated from healthy volunteers using BD Vacu-
tainer Cell Preparation Tubes. Monocytes were isolated 
from PBMCs by plastic adherence method [21], and cul-
tured in RPMI 1640 medium (Gibco, Grand Island, NY) 
with 10  % fetal bovine serum (FBS) (Gibco) and 100 U/
mL penicillin and 100  g/mL streptomycin. Human mac-
rophages were obtained by culturing the monocytes with 
100 ng/mL of macrophage-colony stimulating factor (Bio-
Legend, San Diego, CA) for 4 days. For human monocyte 
derived dendritic cells (HMDCs), monocytes were puri-
fied from PBMCs by magnetic cell sorting using CD14 
microbeads according to the manufacturer’s instructions 
(AutoMACS Pro Separator, Miltenyi Biotec, Teterow, Ger-
many), followed by culturing the monocytes with 20  ng/
mL of granulocyte macrophage-colony stimulating factor 
(PeproTech, Rocky Hill, NJ) and 20 ng/mL of IL-4 (eBio-
science, San Diego, CA) for 5  days. Mouse macrophage 
cell line (RAW264.7) was maintained in DMEM medium 
(Gibco) containing 10  % FBS and antibiotics (penicillin/
streptomycin). Human recombinant Prdx1 (Abnova, Tai-
pei, Taiwan) at 11  μg/mL, LPS (Escherichia coli serotype 
0111:B4, Sigma-Aldrich, St. Louis, MO) at 50  pg/mL, 
Polymyxin B (PMB, Sigma-Aldrich) at 10 μg/mL, human 
and mouse recombinant IFN-γ (R&D Systems) at 20  U/
mL, rabbit polyclonal antibody to Prdx1 (ab59538, Abcam, 
Cambridge, MA) at 2.5 and 10 μg/mL and polyclonol rab-
bit IgG (AB-105-C, R&D system) at 10 μg/mL were added 
to the corresponding cells as described in the figures.
Hypoxic treatment
Human monocytes were incubated in a humidified 
hypoxic chamber (Proox Model 110, Biospherix, Lacona, 
NY) and exposed to hypoxia (5 % CO2 level and less than 
1 % O2 balanced with N2) for 18 or 6 h and followed by 
oxygenation for 24 h. Ambient oxygen concentrations of 
1  % were maintained using a controlled incubator with 
CO2/O2 monitoring and CO2/N2 gas sources. Cells incu-
bated at 5 % CO2 in a humidified atmosphere with 18 % 
O2 were used as normoxic controls.
Statistical analysis
The data were analyzed using SPSS 17.0 (SPSS Inc, 
Chicago, IL). Owing to the non-normal distribution 
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characteristic of most data, the medians and interquartile 
ranges were presented in some figures. Continuous data 
were also expressed as mean ±  standard error of mean 
(SEM) in figures when appropriate. The significant differ-
ences between groups were compared by Mann–Whitney 
U test or Student’s t test. Categorical data were presented 
as percentages of patients and compared using Χ2 test 
or Fisher’s exact test. The correlations were analyzed by 
the Spearmen’s Rho test. Receiver-operating characteris-
tic (ROC) analysis was performed to determine the opti-
mal cut-off values for predicting the primary endpoint 
of 7-day all-cause mortality. The Kaplan–Meier survival 
curve was used to show the survival differences between 
different groups and the log-rank test was used to calcu-
late the statistical significance.
Results
To study the connection between Prdx1 levels and sur-
vival outcomes in victims afflicted with severe cardio-
vascular events, 46 patients who necessitated advanced 
circulation support by ECMO were enrolled. Of the 32 
survivors, 20 patients survived to hospital discharge; 
7 patients were diagnosed with MOF within 7  days of 
ECMO support, and their survival times ranged from 
10  days to 71  days; the other 5 patients died of stroke, 
acute humoral rejection and sepsis-related MOF at day 
8 to day 133. Fourteen patients died mainly from MOF 
within 7  days of ECMO onset. The baseline character-
istics of these patients are shown in Table  1. There was 
no difference between survival and death groups for age, 
gender, risk factors such as coronary artery disease, dia-
betes, smoking, hypertension, diagnosis, and blood white 
cell categories.
Prdx1 levels and hypoxia
Initial Plasma Prdx1 level in the death was 4.3-fold 
higher as that in survival (median 1036.2 vs. 240.8  ng/
mL). Prdx1 in the non-survivors slightly decreased at 
6 and 12 h, and then peaked at 24 h. In contrast, Prdx1 
level in the survivors gradually declined after 2  h of 
ECMO installation. Thereby, the Prdx1 levels between 
these two groups were significantly different through-
out the observational period (Fig. 1a). A hypoxic marker, 
the plasma CA IX, increased in both groups at 2 h when 
the CA IX level in the survivors would reach a plateau, 
whereas, the CA IX level in the deaths increased fur-
ther at 6  h, and attained a significant difference there-
after compared to that in the survivors (Fig.  1b). Total 
ROS production showed no notable difference between 
the survivors and non-survivors at 0–24  h (Additional 
file 2: Figure S2). These results illustrated an early rapid 
release and implied a better prognostic performance of 
Prdx1 than ROS and CA IX in cardiogenic shock patients 
receiving ECMO support. Furthermore, the Prdx1 levels 
were negatively correlated with the ROS activities at 0 h 
(Fig. 2a) while a positive correlation between Prdx1 and 
Table 1 Demographic and  clinical characteristics of  the 
patients in  this study according to  their survival status 
at  7th day after  receiving extracorporeal membrane oxy-
genation support
Values are medians with inter-quartile ranges for continuous data and frequency 
(percentage,  %) for categorical data. The listed P values of statistical tests 
were calculated using Mann–Whitney U test for continuous data and the Χ2 or 
Fisher’s exact test for categorical data
DM diabetes mellitus, CAD coronary artery disease, CPR Cardiopulmonary 
resuscitation, AMI acute myocardial infarction, DCMP dilated cardiomyopathy, 
BPM beat per minute, WBC white blood cell
Variable Survival Death P value
Sample size (n) 32 (69.6 %) 14 (30.4 %)
Age (years) (n = 46) 51.5 (41.5–58.0) 54.7 (48.2–68.2) 0.118
Gender 1.000
 Male (n = 35) 24 (68.6 %) 11 (31.4 %)
 Female (n = 11) 8 (72.7 %) 3 (27.3 %)
Risk factors
 Hypertension (n = 21) 14 (43.8 %) 7 (50.0 %) 0.755
 DM (n = 13) 7 (21.9 %) 6 (42.9 %) 0.171
 CAD (n = 11) 6 (18.8 %) 5 (35.7 %) 0.269
 Smoking (n = 9) 7 (21.9 %) 2 (14.3 %) 0.701
 Dialysis (n = 5) 1 (3.1 %) 4 (28.6 %) 0.078
 Pre‑ECMO CPR (n = 13) 10 (31.3 %) 3 (21.4 %) 0.724
 CPR during ECMO (n = 20) 11 (34.4 %) 9 (64.3 %) 0.105
Diagnosis
 AMI (n = 24) 16 (50.0 %) 8 (57.1 %) 0.754
 DCMP (n = 12) 7 (21.9 %) 5 (35.7 %) 0.467
 Myocarditis (n = 6) 6 (18.8 %) 0 (0.0 %) 0.157
 Other (n = 4) 3 (9.4 %) 1 (7.1 %) 1.000
Heart rate (BPM) (n = 42) 116 (88–138) 96 (66–121) 0.196
Systolic blood pressure 
(mmHg) (n = 40)
90 (74–101) 93 (76–113) 0.902
Diastolic blood pressure 
(mmHg) (n = 40)
57 (47–67) 53 (44–64) 0.435
pH (n = 45) 7.41 (7.30–7.48) 7.23 (7.13–7.39) 0.066
PaCO2 (mmHg) (n = 45) 32 (23–39) 35 (27–46) 0.455
PaO2 (mmHg) (n = 45) 83 (56–156) 108 (60–222) 0.313
HCO3 (mmol/L) (n = 45) 19.3 (15.9–24.0) 17.6 (12.7–19.3) 0.107
Lactate (mmol/L) (n = 43) 6.7 (3.0–9.7) 10.9 (3.3–18) 0.260
Inotropic equivalent (μg/kg/
min) (n = 34)
17.5 (8.2–25.2) 23.3 (18.7–34.4) 0.077
WBC (K/µL) (n = 46) 12.9 (8.7–15.4) 12.3 (9.1–18.4) 0.645
Granulocytes (% of total 
WBC) (n = 46)
72.8 (40.1–82.1) 60.0 (42.2–80.8) 0.856
Lymphocytes (% of total 
WBC) (n = 46)
17.3 (9.0–51.5) 34.2 (11.1–50.1) 0.612
Monocytes (% of total WBC) 
(n = 46)
4.0 (3.2–6.6) 3.9 (2.8–6.4) 0.772
CD14+ CD16+ (% of mono‑
cytes) (n = 46)
64.4 (46.4–82.2) 60.7 (43.7–71.6) 0.314
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CA IX concentrations was detected at later time point 
(Fig. 2b). In addition, the Prdx1 levels at 12 h had a strong 
correlation with the available blood lactate concentra-
tions of 34 patients obtained at 16 h after ECMO installa-
tion (Fig. 2c). The persistently elevated Prdx1 and lactate 
levels could reflect severe tissue hypo-perfusion due to 
insufficient ECMO support. These findings are compat-
ible with the consensus that plasma Prdx1 possesses ROS 
scavenging ability, and probably reflect the severity of tis-
sue hypoxia in this patient cohort.
Prdx1 and systemic inflammatory cytokines
We then compared the plasma levels of TNF-α, IL-1β, 
IL-6, IL-8, IL-10 and MCP-1 in these two groups of 
patients. These inflammatory cytokine levels in the death 
group became significantly higher than the survivors as 
early as 2 h (Fig. 3). ROC analysis (Additional file 3: Figure 
S3A, B) demonstrated that only Prdx1, but not the other 
cytokine levels at 0 h could differentiate all-cause mortal-
ity outcomes on day 7 of these patients, while Prdx1 and 
cytokine levels at 24  h after ECMO support were both 
associated with worse outcomes (Table 2). It was worth 
notice that two optimal cut-off values of plasma Prdx1 
levels at 24 h were obtained by Youden-index. To better 
differentiate the significance of Prdx1 levels as an early 
phase marker for the outcome of the patients recruited 
in current study, we performed Kaplan–Meier survival 
analysis. The result showed that plasma Prdx1 levels were 
very informative in predicting the eventual outcome of 
cardiogenic shock patients receiving ECMO support. 
The patients with Prdx1 levels lower than the optimal 
cut-off values at 0 h (Fig. 4a) and 24 h (Fig. 4b) had bet-
ter outcomes in both the 7-day and 30-day overall sur-
vivals than the patients whose Prdx1 levels were higher 
than those cut-off values. Similarly, patients with lower 
initial Prdx1 had better chance of maintaining event 
free survivals during a short term (7-day) and a long 
term (30-day) observation period (Additional file 4: Fig-
ure S4A, B). Correlation analysis revealed that plasma 
Prdx1 measured at 2–24  h correlated well with all the 
cytokines except IL-1β at the corresponding time points 
(Table 3). This result inferred that plasma Prdx1 could be 
an upstream inducer of these cytokines.
TLR4 signaling activation
We measured TLR4 and CD14 expressions of the last 33 
consecutive patients we recruited in this study. The sur-
face expression levels of TLR4 and CD14 on the mono-
cytes of the death group were significantly higher at 2 h 
than those in the survivors, and this difference seemed 
to level off at later time points (Fig.  5a, b). Intriguingly, 
plasma Prdx1 concentrations examined at 0, 2 and 
24  h correlated positively to TLR4 expression levels on 
monocytes at the corresponding time points (Fig.  5c), 
indicating a functional relationship between Prdx1 and 
its receptor system evolved during the early phase of 
patients with severely compromised cardiovascular func-
tion. In addition, a positive correlation between mono-
cyte TLR4 and CD14 levels was also noted throughout 
the course of observation (Fig. 5d). Taken together, Prdx1 
might trigger or stabilize a formation of complexes with 
its receptor and co-receptor on the cellular membrane of 
its target cells.
rPrdx1 induced cytokine secretions from IFN‑γ priming 
macrophages
Given the above results, we hypothesized that Prdx1 
could induce cytokine production. To investigate this 
Fig. 1 Peroxiredoxin 1 was an early phase predictor for the clinical 
outcomes of cardiogenic shock patients who received ECMO resus‑
citation. Plasma Peroxiredoxin 1 (Prdx1) (a) and carbonic anhydrase 
IX (CA IX) (b) levels in the cardiogenic shock patients at the indicated 
time points after receiving ECMO support according to their 7‑day 
survival status [survivors (n = 32) vs. non‑survivors (n = 14)]. Data 
were expressed as median and interquartile range, while solid circle 
and open triangle indicated mild and extreme outliers respectively. 
Statistical differences between groups were analyzed by Mann–Whit‑
ney U test
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Fig. 2 Correlation between Prdx1 and hypoxic markers. Plasma Prdx1 levels in the patients cohort as described in Fig. 1 were negatively related to 
ROS levels (a) at 0 h, but positively related to plasma CA IX (b) at 24 h after receiving ECMO support. Prdx1 levels at 12 h was also positively related 
to blood lactate (c) measured at 16 h after ECMO initiation in 34 patients. The correlations were analyzed by the Spearmen’s Rho test, with dashed 
lines indicating the 95 % confidence interval
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Fig. 3 Comparison of inflammatory cytokine profiles between survivors and non‑survivors who received ECMO support. Plasma IL‑6, IL‑8, IL‑10, 
monocyte chemotactic protein‑1 (MCP‑1), tumor necrosis factor‑α (TNF‑α), and IL‑1β levels were assessed among survivors (n = 32, open boxes) and 
non‑survivors (n = 14, grey boxes) at the indicated time points after implement of ECMO support. Data represented the median and interquartile 
range of each group, while solid circle and open triangle indicated mild and extreme outliers respectively. Statistical differences between groups 
were analyzed by Mann–Whitney U test
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possibility, recombinant human Prdx1 (rPrdx1) was 
added to HMDCs. Indeed, IL-6 was moderately induced 
(Fig.  6a) although not to the extent as elicited by LPS 
(Fig.  6b). This result was not due to a contamination of 
bacterial endotoxin during preparation of the recombi-
nant protein, because PMB did not block this effect. In 
contrast, the IL-6 induced by LPS could be significantly 
inhibited by PMB (Fig.  6a, b). rPrdx1 also induced IL-6 
secretion from human macrophages, and the effect was 
augmented by pre-incubation of the cells with IFN-γ for 
18 h (Fig. 6c). This IFN-γ-priming effect was also evident 
in rPrdx1 or LPS-induced TNF-α secretion from mouse 
macrophage RAW264.7 cells (Fig. 6d).
Hypoxia enhanced rPrdx1‑induced cytokine secretions 
from monocytes
In order to determine the role of hypoxia/reoxygena-
tion in cytokine production by Prdx1, we pretreated 
human monocytes with hypoxia (1  % O2) for 18  h fol-
lowed by normoxia for 24  h in the absence or pres-
ence of rPrdx1. As shown in Fig.  7a, rPrdx1 induced a 
marginal IL-6 secretion from monocytes, but this effect 
could be greatly augmented by hypoxia/reoxygenation. 
Although increased IL-6 secretion was also observed 
in the absence of rPrdx1 addition (Fig.  7a), the release 
of endogenous Prdx1 induced by hypoxia/reoxygena-
tion treated monocytes may account for this elevation of 
IL-6 (Fig.  7b). rPrdx1 had insignificant effect on TNF-α 
secretion in monocytes under normoxia, whereas it was 
able to induce TNF-α secretion from hypoxia/reoxy-
genation treated monocytes (Fig.  7c). Reoxygenation 
for 24 h following a shorter period of hypoxia treatment 
(6 h) induced TLR4 and CD14 expressions on monocytes 
(Fig. 7d).
Prdx1 stimulated IL‑6 secretion under hypoxia/
reoxygenation treatment
Although IL-6 secretion increased after hypoxia/reoxy-
genation in monocytes (Fig. 7a) and hypoxia also induced 
Prdx1 (Fig. 7b), the physiological significance of Prdx1 in 
the induction of IL-6 during hypoxia remains elusive. To 
address the definitive role of Prdx1 in hypoxia-induced 
Table 2 Predictive values of peroxiredoxin 1 and cytokines for 7-day all cause mortality rate
Cut-off values are determined by receiver-operating characteristic (ROC) analysis
Prdx peroxiredoxin, CA carbonic anhydrase, IL interleukin, MCP monocyte chemotactic protein, TNF tumor necrosis factor, AUC area under the ROC curve, SE standard 
error, CI confidence interval
Biomarkers Cut‑off (ng/mL) AUC SE 95 % CI Sensitivity Specificity P value
0 h
 Prdx1 759.09 0.734 0.092 0.56–0.91 0.692 0.774 0.015
 CA IX 0.123 0.531 0.091 0.35–0.71 0.769 0.419 0.748
 IL‑6 0.839 0.618 0.112 0.40–0.84 0.462 0.903 0.222
 IL‑8 0.333 0.524 0.101 0.33–0.72 0.308 0.839 0.807
 IL‑10 0.245 0.526 0.103 0.32–0.73 0.308 0.903 0.787
 MCP‑1 0.211 0.618 0.098 0.43–0.81 0.615 0.677 0.222
 TNF‑α 0.0013 0.653 0.090 0.48–0.83 0.462 0.839 0.114
 IL‑1β 0.019 0.600 0.104 0.40–0.81 0.308 1.000 0.298
24 h
 Prdx1 59.78 0.861 0.059 0.75–0.98 1.000 0.567 <0.001
1027.23 0.667 0.900
 CA IX 0.466 0.811 0.065 0.68–0.94 1.000 0.567 0.002
 IL‑6 0.984 0.883 0.062 0.75–1.00 0.750 0.900 <0.001
 IL‑8 0.208 0.881 0.064 0.75–1.00 0.917 0.800 <0.001
 IL‑10 0.083 0.861 0.071 0.72–1.00 0.917 0.767 <0.001
 MCP‑1 1.223 0.856 0.088 0.00–1.00 0.833 0.933 <0.001
 TNF‑α 0.0020 0.828 0.076 0.68–0.98 0.833 0.833 0.001
 IL‑1β 0.0043 0.736 0.081 0.58–0.90 0.667 0.700 0.018
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Fig. 4 High initial Peroxiredoxin 1 level in cardiogenic shock patients who received ECMO support was associated with a poorer survival. Kaplan–
Meier survival analysis of 7‑ and 30‑day overall survivals in cardiogenic shock patients categorized by the cut‑off values, as presented in Table 2, of 
their plasma Prdx1 levels at 0 (a) and 24 h (b) after receiving ECMO support
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production of IL-6 and explore the potential therapeutic 
possibility, we applied Prdx1 specific antibody to mono-
cytes after hypoxic challenge. As seen in Fig.  8, Prdx1 
antibody at 2.5–10 μg/mL, but not the control immuno-
globulin, drastically inhibited the secretion of IL-6. This 
result reinforced our previous conclusion that the IL-6 
released by hypoxia/reoxygenation treated human mono-
cytes is due to the stimulation of Prdx1, and thus demon-
strated that Prdx1 might serve as a potential therapeutic 
target aimed at alleviating cytokine storm under severe 
tissue hypoxia situation such as those cases receiving 
ECMO supports.
Discussion
In the present study, we showed for the first time that 
plasma Prdx1 was linked to poor outcomes in patients 
with cardiogenic shock undergoing ECMO. Prdx1 was 
also correlated to blood lactate and plasma CA IX lev-
els, possibly reflecting a profound and irreversible 
hypoxic damage occurring in the non-survivors. Like 
other DAMPs, Prdx1 in circulation can be released from 
necrotic cells and/or secreted actively by stressed cells 
[22, 23]. Additionally, it was shown that only the oxidized 
Prdx1 can be secreted from cells encountering certain 
oxidant or inflammatory stimuli [24]. Thus, plasma Prdx1 
may reflect the extent of oxidative stress. The inverse 
correlation between Prdx1 and ROS levels before the 
initiation of ECMO signifies that Prdx1 may intensely 
participate in the intracellular ROS scavenging for car-
diogenic shock patients. The positive correlation between 
high initial Prdx1 level and early phase mortality rate in 
cardiogenic shock patients undergoing ECMO support 
is, however, surprising given the assumption that Prdx1 is 
a protective ROS scavenger [14]. A possible explanation 
for this paradox might rely on the biochemical nature of 
the Prdx1 found in the circulation of hypoxic patients. 
It has been reported that secretion of Prdx1 is through 
a redox-dependent mechanism involving cysteine oxida-
tion [17]. Thereby, the high Prdx1 found in the plasma of 
non-survivors in our cohort might belong to a population 
of oxidized molecules which have already or temporarily 
lost their ROS scavenging capability. Therefore, further 
studies to identify the redox status of Prdx1 in plasma are 
mandatory for clarifying their extracellular roles beyond 
their established intracellular role as a ROS scavenger.
Overwhelming production of pro-inflammatory 
cytokines can activate interaction of circulating leuko-
cytes and vascular endothelial cells, and result in leuko-
cyte-dependent microvascular injury which is a major 
feature of I/R injury and MOF [4]. Though it is well rec-
ognized that prolonged ischemia causes tissue and organ 
damage, the injury induced by reperfusion may be even 
more detrimental. Our study found a rapid burst of vari-
ous plasma cytokines within 2 h of ECMO regardless of 
the clinical outcomes, implying a release of pre-formed 
cytokines from tissue stores, as described in a porcine 
model with ECMO institution [25]. The half-lives of 
plasma cytokines are generally less than 2 h [26]. Hence 
the rising cytokine levels which persisted for 1 day in the 
non-survivors of this study may reflect the synthesis and 
continuous release of these de novo cytokines during the 
ECMO support. Consequently, plasma cytokine levels at 
24 h could provide better prognostic information beyond 
that of early time points (Table 2). It is worth note that 
optimal cut-off values of Prdx1 at 0  h could differenti-
ate the outcomes of both the 7 and 30  days overall and 
event-free survivals (Fig. 4; Additional file 4: Figure S4), 
implying that early measurements of Prdx1 in cardio-
genic shock patients could provide prognostic informa-
tion during the course of ECMO application.
Table 3 Correlations between  plasma peroxiredoxin 1 
and  cytokines in  cardiogenic shock patients at  the indi-
cated time points after receiving extracorporeal oxygena-
tion membrane support
Values are Spearman’s correlation coefficients, * P < 0.05 and ** P < 0.01, 
respectively
Prdx peroxiredoxin, IL interleukin, MCP monocyte chemotactic protein, TNF 
tumor necrosis factor
Prdx1 0 h 2 h 6 h 12 h 24 h
IL‑6 0.155 0.637** 0.612** 0.648** 0.616**
IL‑8 −0.002 0.481** 0.565** 0.650** 0.653**
IL‑10 −0.026 0.573** 0.571** 0.704** 0.684**
MCP‑1 0.098 0.425** 0.553** 0.463** 0.600**
TNF‑α 0.337* 0.476** 0.373** 0.599** 0.710**
IL‑1β 0.052 0.187 0.330* 0.251 0.179
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The role of Prdx1 is not confined to its antioxidant 
activities. Interaction of ligand and receptor is the leading 
facet for the functional study of extracellular Prdx1 [27]. 
In vitro experiment demonstrates that binding of Prdx1 
to TLR4 on mouse macrophages occurs within minutes 
and results in internalization of both molecules [12]. The 
internalization of Prdx1/TLR4 complex is similar to the 
endocytosis of LPS/TLR4 which is known to modulate 
multiple purposes of receptor signaling, including TLR4 
recycling or degradation for signal sensitivity [28, 29]. As 
Fig. 5 Interaction of TLR4, CD14 and Prdx1 in cardiogenic shock patients who received ECMO support. Monocyte TLR4 (a) and CD14 (b) surface 
expressions [median and interquartile range of the mean fluorescence intensity (MFI) as assessed by flow cytometry analysis] at the indicated time 
points in 24 survivors (open boxes) and 9 deaths (grey boxes). c TLR4 expression on monocytes was found best correlated to the Prdx1 levels at 24 h 
after initiating ECMO support (correlation coefficient = 0.425, P = 0.015, indicated by solid circle and line). Similarly, plasma Prdx1 levels at 0 and 2 h 
were also noted to be positively related (indicated by dotted lines). d TLR4 and CD14 expressions were found positively correlated to each other at 
all the time points through the observation course within 24 h. The dotted lines indicated the linear fits for the correlation of both variables at each 
time point. Solid circles and line indicated 6 h after initiating ECMO support was the time point with the strongest correlation between TLR4 and 
CD14 expression on the monocytes of patients (correlation coefficient = 0.699, P < 0.001)
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shown in Fig. 5, TLR4 expressions were higher in death 
group at 2 h, and this difference diminished at later time 
points, indicating a rapid dynamic change of this recep-
tor on monocyte membrane after ECMO installation. 
It has been reported that CD14 is required for opti-
mal cytokine secretions in response to Prdx1 [12] and 
is also essential for TLR4 endocytosis triggered by LPS 
[30, 31]. Accordingly, the finding of positive correlation 
between monocyte CD14 and TLR4 fluorescence intensi-
ties in this study can be regarded as a likely indication for 
ligand/receptor complex cooperation and internalization, 
which can also be seen in patients with on-pump coro-
nary artery bypass surgery [32].
A good correlation between Prdx1 and cytokine levels 
at every time point after ECMO support (Table 3) evoked 
that circulating Prdx1 may be an important mediator in 
the development of ECMO-related SIRS. Our in  vitro 
experiments proved that rPrdx1 indeed induced IL-6 
and TNF-α release from macrophages. Moreover, 
IFN-γ  priming  together with  rPrdx1 can further stimu-
late  this inflammatory  response, consolidating the evi-
dence that Prdx1 acts as a pro-inflammatory initiator.
Although hypoxia is known to regulate the synthesis 
of Prdx1 [33], our finding that the release of endogenous 
Prdx1 from hypoxia/reoxygenation treated monocytes 
is novel. Several endogenous TLR4 ligands have been 
shown in patients with ischemic heart diseases that 
increase pro-inflammatory cytokine productions and 
are associated with disease severity [34–37]. Therefore, 
in order to testify whether Prdx1 is a previously unher-
alded danger signal in I/R injury, neutralization of Prdx1 
using specific antibody was performed to examine the 
Fig. 6 Prdx1 induce IL‑6 and TNF‑α production in INF‑γ primed macrophage. Human recombinant Prdx1 (rPrdx1) at 11 μg/mL (a) or LPS (50 pg/mL) 
(b), that was either pretreated with PMB (10 μg/mL) or not, was added to human monocyte derived dendritic cells for 24 h before the culture super‑
natants were collected and analyzed for IL‑6 levels. INF‑γ (20 U/mL) pretreated human monocyte derived macrophages (c) or mouse macrophage 
RAW264.7 cells [12] were incubated with Prdx1 (11 μg/mL) or LPS (50 pg/mL) for 24 h before the supernatants were harvested and analyzed for 
IL‑6 (c) or TNF‑α [12] levels. Solvent vehicles diluted in the culture media were used as the negative controls. Data represented means of triplicate 
samples; error bars represented SEMs. *P < 0.05, and ***P < 0.001
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pro-inflammatory effect of Prdx1 (Fig.  8). Apparently, 
the dramatic inhibition of IL-6 secretion with neutrali-
zation antibody indicates that Prdx1 may play a critical 
role in the pathogenesis of I/R related SIRS by promot-
ing inflammation and serve as a novel candidate for the 
development of therapies against I/R injury.
Conclusions
For the first time, we discovered the early prognostic role 
of plasma Prdx1 in cardiogenic shock patients receiving 
ECMO and revealed the correlation of Prdx1 between 
innate immunity receptors and tissue hypoxia. In  vitro 
investigation  showed that Prdx1 might play a role in 
Fig. 7 Hypoxia enhanced Prdx1‑induced IL‑6 and TNF‑α production. Human monocytes, cultured under normoxia or hypoxia condition for 18 h, 
were incubated either with solvent control or rPrdx1 (11 μg/mL) for another 24 h in normoxia before the supernatants were harvested and analyzed 
for IL‑6 (a) and TNF‑α (c) levels. b The culture supernatants from human monocytes, under normoxia or hypoxia condition for 18 h and then fol‑
lowed by another 24 h in normoxia, were harvested and analyzed for the Prdx1 levels. d Human monocytes, cultured under normoxia or hypoxia 
condition for 6 h, were further incubated in normoxia for 24 h before surface TLR4 and CD14 expressions were analyzed. Data represented means 
and SEM for triplicate samples. *P < 0.05, **P < 0.01, and ***P < 0.001
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the regulation of  proinflammatory cytokine expressions 
and could be a potential therapeutic target for treating 
ischemia/reperfusion injury.
Additional files
Additional file 1: Figure S1. CD14 and TLR4 expressions on CD14+ 
monocytes analyzed by flow cytometry. (A) A representative forward (FSC) 
and side scattering (SSC) plot of lymphocytes (R1), monocytes (R2) and 
granulocytes (R3) was shown. (B) Isotype control antibody was used to 
establish the background fluorescence levels of monocytes (M1), and the 
percentage of positive cells was determined after staining of the cells with 
specific antibody (M2). (C) The CD14+ monocytes population was gated 
as in the SSC/CD14 dot plot. The CD14 (D) and TLR4 (E) expression levels 
were calculated as mean fluorescence intensity (MFI) of the populations 
as gated using the methodology described for panel B.
Additional file 2: Figure S2. ROS levels in the cardiogenic shock 
patients who received ECMO support. Blood ROS levels were detected by 
luminol at the indicated time points after receiving ECMO support accord‑
ing to their 7‑day survival status [survivors (n = 32) vs. non‑survivors (n = 
14)]. Data were expressed as median and interquartile range, solid circle 
and open triangle indicated mild and extreme outliers respectively. Statis‑
tical differences between groups were analyzed by Mann–Whitney U test.
Additional file 3: Figure S3. ROC analysis for potential biomarkers in 
predicting outcome of patients with cardiogenic shock receiving ECMO 
support. ROC curves for plasma biomarkers measured at 0 hr (A) and 24 hr 
(B) after ECMO support to differentiate the 7‑day mortality.
Additional file 4: Figure S4. High initial Peroxiredoxin 1 level in cardio‑
genic shock patients who received ECMO support was associated with a 
poorer event‑free survival. Kaplan–Meier survival analysis of 7‑ and 30‑day 
event free survivals in cardiogenic shock patients categorized by the 
cut‑off values, as presented in Table 2. Event free survivals: survival status 
without multiple organ failure under the condition when assessment of 
sequential organ failure assessment (SOFA) score was lower than 15.
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